Eurosurveillance remains in the updated list of the Directory of Open Access Journals (DOAJ). It was first added to the DOAJ on 9 September 2004. Eurosurveillance is also listed in the Securing a Hybrid Environment for Research Preservation and Access / Rights MEtadata for Open archiving (SHERPA/RoMEO) [2], a database which uses a colour‐coding scheme to classify publishers according to their self‐archiving policy and to show the copyright and open access self-archiving policies of academic journals. Eurosurveillance is listed there as a ‘green’ journal, which means that authors can archive pre-print (i.e. pre-refereeing), post-print (i.e. final draft post-refereeing) and archive the publisher's version/PDF.

Follow Eurosurveillance on Twitter: @Eurosurveillanc

Read our articles on Zika virus infection

Note of concern published for 'Epidemiological investigation of MERS-CoV spread in a single hospital in South Korea, May to June 2015',

In this issue

Home Eurosurveillance Edition  2008: Volume 13/ Issue 2 Article 3
Back to Table of Contents
Previous Download (pdf)

Eurosurveillance, Volume 13, Issue 2, 10 January 2008
Rapid communications
Food-borne viruses in Europe network report: the norovirus GII.4 2006b (for US named Minerva-like, for Japan Kobe034-like, for UK V6) variant now dominant in early seasonal surveillance
  1. on behalf of the Food-borne Viruses in Europe network (
  2. National Institute for Public Health and the Environment, Center for Infectious Disease Control, Bilthoven, the Netherlands

Citation style for this article: Siebenga J, Kroneman A, Vennema H, Duizer E, Koopmans M. Food-borne viruses in Europe network report: the norovirus GII.4 2006b (for US named Minerva-like, for Japan Kobe034-like, for UK V6) variant now dominant in early seasonal surveillance. Euro Surveill. 2008;13(2):pii=8009. Available online:


Institutes charged with the surveillance of norovirus (NoV) outbreaks in Ireland, Germany, the Netherlands and Sweden reported high NoV activity to the European Food-borne Viruses in Europe network (FBVE) in late 2007. In these countries, the number of reported NoV outbreaks exceeds that of October and November of the previous record seasons, 2004 and 2006. A similar situation has been reported in the United Kingdom (UK) [1]. In recent years, most norovirus outbreaks have been caused by GII.4 strains. These viruses evolve rapidly by genetic mutation coupled with selective pressure. The rapid evolution of GII.4 noroviruses resulting in the successive emergence of new variants has been observed since 2002. In the norovirus outbreak season of 2006–7, two variants emerged that co-circulated. Early observations for the 2007–8 season suggest that one of these variants now dominates. The currently circulating strains have mutations that set them apart from the older strains, leading to one amino acid change in the capsid sequence. Although we do not consider the strains that currently circulate as new variants, based on the global character of norovirus and previous experience with high numbers of reported outbreaks we are expecting high norovirus activity in other countries.

Noroviruses are known as a common cause of diarrhea and vomiting, often in outbreaks and predominantly in winter. Studies across the world have shown that in recent years most outbreaks have been caused by strains belonging to a particular genotype of noroviruses, named GII.4. The GII.4 strains evolve rapidly and are further subdivided into variants. Since 1995, three variants have emerged and replaced each other globally, in 1995, 2002, and 2004. In 2006, two variants emerged that co-circulated. Characterisation studies suggest that lineages evolve through selective pressure and are likely to be antigenic variants (drift variants) [2].

For international communication, standardized nomenclature of variant types is needed. This was discussed and agreed at the Third Calicivirus Meeting in Cancun, Mexico, November 2007, and a working group chaired by the Netherlands’ National Institute for Public Health and the Environment (RIVM) with representatives from the United States, Canada, Australia and Japan will prepare a unifying proposal for this in the coming months. Table 1 lists the currently used names for reference for the different variants across the world.

Situation in Europe in the first part of the current season 2007–8
In the last norovirus outbreak season of 2006–7, two variants of GII.4 NoV circulated in Europe, causing the majority of viral gastroenteritis outbreaks [2]. These variants, named GII.4-2006a and GII.4-2006b in the FBVE network (Table 1), were found at approximately equal proportions in most European countries in the winter of 2006–7 [2]. Consensus sequences – the common sequences derived from multiple alignments of all strains belonging to each variant or genotype – of region A (part of the polymerase gene) and C (part of the capsid gene) and background information can be found at: These regions are the genome targets that are most often used for genotyping across the world. The consensus sequences are freely available from the public part of the website.

During the summer and autumn of 2007, the GII.4-2006b variant (in the United States named Minerva-like, in Japan Kobe034-like, in the UK V6) became dominant over the GII.4-2006a variant, and several countries reported a high number of outbreaks in October and November. Currently the two variants still co-circulate, but GII.4-2006b now seems more prevalent in most European countries. In the Netherlands in October 2007, 29 NoV outbreaks were reported to the RIVM, of which 26 were genotyped. Of these 3 (11.5%) were GII.4-2006a and 12 (46%) were GII.4-2006b. In November, 46 outbreaks were reported. To date, 30 of these have been genotyped, and of those 3 (10%) were GII.4-2006a and 22 (73%) were GII.4-2006b.

The recent GII.4-2006b strains contain two mutations in region A (T4387C and T4543C, Lordsdale numbering, X86557) and one mutation in region C (A68C, numbering starts at ATG of GII.4 capsids) discriminating them from older GII.4-2006b strains. The mutation in region C results in an amino acid mutation (N23S, numbering starts at ATG of GII.4). The sequences for these strains of region A and C are displayed in Figures 1 and 2.

In Figure 3, an overview is given of the new strains isolated from outbreaks reported so far per country and per month of onset of the outbreak. The line (right axis) represents the fraction of all GII.4 outbreak strains which hold the observed mutations.

Most countries within the network sequence region A (polymerase) of the virus, in some cases both region A and region C sequences are determined from one outbreak. Ireland and Sweden only perform region C (capsid) sequencing.

The first outbreaks with these characteristics were reported from Ireland in December 2006. From October 2007, the numbers of outbreaks rose sharply in several other European countries. The number of outbreak reports in the most recent months are expected to increase significantly because most countries in the FBVE network are only able to report sequences one or two months after the date of onset of the outbreak. Analogous to the situation in the autumn of 2004 and 2006, this indicates a highly active norovirus winter season [3,4].

Strain characterisation, capsid sequences
Additional genome sequencing of two strains that have the mutations in region A showed that the amino acid mutation in region C is the only amino acid mutation in the capsid gene. Therefore, the current high level of seasonal activity can not be explained by introduction of new antigenic variants.

The mutations we determined in regions A and C that set the latest strains apart from the earlier strains of the 2006b variant are probably not related to the changes in dominance and may simply be fixed along with other neutral mutations. We previously observed similar changes in dominance of strains and this was usually accompanied by amino acid changes in the P2 domain of the capsid protein. The earlier strains of the 2006b variant had several differences in the P2 domain compared to all other GII.4 variants circulating in previous years. However, when it first emerged, it was not able to displace the co-circulating 2006a variant, suggesting that its ability to infect and subsequently spread was not yet optimal. The observations at the start of this season suggest that the 2006b variant has gained fitness over the last year, since it has become dominant.

The start of the norovirus season shows a high incidence of outbreaks across Europe, caused mostly by GII.4 viruses belonging to a variant that emerged globally in 2006. It remains unclear if the record high reporting is a surveillance artifact or reflects changes in the epidemiology of GII.4 strains, although in recent years GII.4 viruses have evolved rapidly by mutation. Given the high incidence of norovirus infections in the general population, introduction into health-care settings is inevitable. Immediate action when cases are reported and stringent hygiene measures can reduce the size of outbreaks in healthcare settings.



  1. British Broadcasting Corporation. Stomach bug sweeping the country. 3 January 2008. Online press article. Available from:
  2. Siebenga JJ, Vennema H, Renckens B et al. Epochal evolution of GGII.4 norovirus capsid proteins from 1995 to 2006. J Virol 2007; 81(18):9932-41.
  3. Kroneman A, Vennema H, Harris J, Reuter G, von Bonsdorff C, Hedlund K, Vainio K, Jackson V, Pothier P, Koch J, Schreier E, Böttiger B, Koopmans M, Food-borne viruses in Europe network. Increase in norovirus activity reported in Europe. Euro Surveill 2006;11(12):E061214.1. Available from:
  4. Kroneman A, Vennema H, van Duijnhoven Y, Duizer E, Koopmans M. High number of norovirus outbreaks associated with a GGII.4 variant in the Netherlands and elsewhere: does this herald a worldwide increase?. Eurosurveillance Weekly [1812-075X]. 2004 Dec 23;12(52) 041223. Available from:


Back to Table of Contents
Previous Download (pdf)

The publisher’s policy on data collection and use of cookies.

Disclaimer: The opinions expressed by authors contributing to Eurosurveillance do not necessarily reflect the opinions of the European Centre for Disease Prevention and Control (ECDC) or the editorial team or the institutions with which the authors are affiliated. Neither ECDC nor any person acting on behalf of ECDC is responsible for the use that might be made of the information in this journal. The information provided on the Eurosurveillance site is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician. Our website does not host any form of commercial advertisement. Except where otherwise stated, all manuscripts published after 1 January 2016 will be published under the Creative Commons Attribution (CC BY) licence. You are free to share and adapt the material, but you must give appropriate credit, provide a link to the licence, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.

Eurosurveillance [ISSN] - ©2007-2016. All rights reserved

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.